Investing.com - Halozyme reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Halozyme announced earnings per share of $0.74 on revenue of $209M. Analysts polled by Investing.com anticipated EPS of $0.32 on revenue of $189.72M.
Halozyme shares are down 35% from the beginning of the year and are trading at $47.75 , down-from-52-week-high.
Halozyme shares gained 4.19% in after-hours trade the report.
Halozyme follows other major Healthcare sector earnings this month
Halozyme's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar